Key result
Compound 14m reduces fibrosis and inflammation in rat renal fibroblasts via stable NOX4 binding.
Why the study?
NOX4 has emerged as a promising target for developing drugs to tackle renal fibrosis, necessitating novel inhibitors for therapeutic development.
Compound 14m is a novel NOX4 inhibitor that reduces ROS levels and ameliorates fibrosis and inflammation in a rat renal fibroblast model.
Answers are grounded in this paper and cite their sources.
Supports preclinical optimization of 14m; leaves open clinical translation for renal fibrosis.
Nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4) has emerged as a promising target for developing drugs to tackle renal fibrosis. In this study, a series of chromone derivatives were designed and synthesized. Additionally, we established a NOX4 overexpression model using the NRK-49F rat renal fibroblasts cell line and identified compound 14m as highly active through the assessment of intracellular reactive oxygen species (ROS) levels in this model. The drug affinity responsive target stability (DARTS) assay illuminated the robust binding stability of 14m with NOX4. Mechanistic studies further substantiated its efficacy in ameliorating fibrosis and inflammation. This investigation positions 14m as a noteworthy NOX4 inhibitor, shedding light on its regulatory role in renal fibroblasts. Importantly, it diversifies the structural landscape of NOX4 inhibitors, offering novel lead compounds for future development.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2024) studied Renal fibrosis. Compound 14m (chromone derivative) was evaluated on Intracellular reactive oxygen species (ROS) levels and binding stability with NOX4. Compound 14m demonstrated robust binding stability with NOX4 and efficacy in ameliorating fibrosis and inflammation in a rat renal fibroblast model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: